Related Experiment Video
Updated: Jun 21, 2026
05:51
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development
1Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Summary
Translational readthrough drugs can restore functional proteins by suppressing premature termination codons (PTCs), offering a promising strategy for genetic disorders like cystic fibrosis.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Premature termination codons (PTCs) arise from base pair substitutions, creating abnormal stop codons and leading to genetic disorders.
- PTCs result in the production of truncated, non-functional proteins, underlying numerous inherited diseases.
Purpose of the Study:
- To review the mechanisms of PTC suppression by drugs that induce translational readthrough.
- To examine the role of ribosome interactions, mRNA context, and transcript regulation in PTC suppression.
- To evaluate proof-of-concept studies and clinical trial results for PTC suppression therapies.
Main Methods:
- Review of existing literature on translational readthrough agents and their interaction with the eukaryotic ribosome.
- Analysis of preclinical model systems and clinical trial data, with a focus on PTC124.
- Examination of studies investigating PTC suppression in genetic diseases, including cystic fibrosis.
Main Results:
- Several drugs, including aminoglycosides and novel small molecules, induce translational readthrough of PTCs.
- Studies in cystic fibrosis models show improvements in CFTR biomarkers with aminoglycoside and PTC124 treatments.
- Understanding PTC suppression mechanisms is advancing therapeutic strategies for genetic diseases.
Conclusions:
- Translational readthrough represents an innovative therapeutic strategy for genetic disorders caused by PTCs.
- Further research into PTC suppression mechanisms will guide the development of effective treatments.
- Targeting translation termination offers a novel approach to restoring protein function in genetic diseases.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:27Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...